SINGAPORE – Shingles vaccine Shingrix will soon be made more affordable for eligible Singaporeans and Permanent Residents (PR ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

In its first set of financial figures since spinning off its consumer health division, GSK has reported a 19% increase in revenues, driven by burgeoning demand for its shingles vaccine Shingrix ...

If the vaccine works and is developed as rapidly as Pfizer and BioNTech hope, it could spell trouble for GSK, which is depending on Shingrix to drive revenues as it works towards rolling out a ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...

继带状疱疹减毒活疫苗获得许可至今，尚无其他疱疹病毒治疗疫苗获得批准。

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

GSK PLC (GSK) reports robust sales and profit growth, while navigating external pressures in the vaccine market and preparing for future product approvals.

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company ...